Viva Biotech (Shanghai)

Industry

  • Biotechnology
    • Drug Discovery Technologies
      • Molecular Diversity
  • Contract Research Organization-CRO

Other Names/Subsidiaries

  • Zhejiang Langhua Pharmaceutical
See more in Biomedtracker

Latest on Viva Biotech (Shanghai)

Scrip

Full-Life Expands Radiopharmaceutical Reach With $245m Focus-X Buyout

 
• By Dexter Jie Yan

On 29 November, Shanghai-based Full-Life Technologies Limited announced it would acquire Focus-X Therapeutics, a two-year-old US biotech focusing on the development of peptide receptor radionuclide

Scrip

Deal Watch: Bausch Health Takes Option To Allegro Dry AMD Candidate

 
• By Joseph Haas, Alex Shimmings, and Brian Yang

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bausch Makes $50m Commitment For Risute

Scrip

Finance Watch: 2020 Is Four Biopharma IPOs Away From Matching 2019

 
• By Mandy Jackson

It will take only four more initial public offerings in the US by biopharmaceutical companies for 2020 to match the full-year total of 50 drug developer IPOs in 2019. First-time offerings by Kymera T

Scrip

Asia Deal Watch: Simcere, G1 Partner Globally On Myelopreservation Drug

 
• By Joseph Haas and Ian Haydock

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Simcere Acquires China-Plus Rights To G